2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2010
Comorbid major depression in obsessive-compulsive disorder patients
Quarantini L, Torres A, Sampaio A, Fossaluza V, de Mathis M, do Rosário M, Fontenelle L, Ferrão Y, Cordioli A, Petribu K, Hounie A, Miguel E, Shavitt R, Koenen K. Comorbid major depression in obsessive-compulsive disorder patients. Comprehensive Psychiatry 2010, 52: 386-393. PMID: 21087765, DOI: 10.1016/j.comppsych.2010.09.006.Peer-Reviewed Original ResearchConceptsMajor depressive disorderObsessive-compulsive disorderOCD patientsCurrent major depressive disorderComorbid major depressive disorderLifetime major depressive disorderComprehensive psychiatric evaluationComorbid major depressionSevere general psychopathologyHigher severity scoresObsessive-compulsive disorder patientsSymptom dimensionsOCD symptom dimensionsClinical characteristicsFrequent complicationSeverity scoreDepressive disorderMajor depressionPrevalence ratesPsychiatric evaluationDisorder patientsPatientsGeneral psychopathologyDisordersOCD symptoms
2009
Validation of the University of São Paulo Sensory Phenomena Scale:Initial Psychometric Properties
Rosario MC, Prado HS, Borcato S, Diniz JB, Shavitt RG, Hounie AG, Mathis ME, Mastrorosa RS, Velloso P, Perin EA, Fossaluza V, Pereira CA, Geller D, Leckman J, Miguel E. Validation of the University of São Paulo Sensory Phenomena Scale:Initial Psychometric Properties. CNS Spectrums 2009, 14: 315-323. PMID: 19668122, DOI: 10.1017/s1092852900020319.Peer-Reviewed Original ResearchConceptsOpen clinical interviewClinical InterviewYale-Brown ObsessiveObsessive-compulsive disorderFourth Edition Axis I DisordersEarly-onset OCD patientsYale Global Tic Severity ScaleSensory phenomenaCompulsive ScaleOCD patientsOCD subjectsAxis I DisordersTic Severity ScaleSão Paulo Sensory Phenomena ScaleSignificant differencesBeck Depression InventoryBeck Anxiety InventorySeverity scoreI disordersInter-rater reliabilityInitial psychometric propertiesSeverity ScalePremonitory urgesPatientsDepression InventoryObsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol
R. A, Hounie A, Sampaio A, Arrais J, Miguel E, Elkis H. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Comprehensive Psychiatry 2009, 50: 437-442. PMID: 19683614, DOI: 10.1016/j.comppsych.2008.11.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsAntipsychotic AgentsClozapineComorbidityDiagnostic and Statistical Manual of Mental DisordersDrug Therapy, CombinationFemaleHaloperidolHumansInterview, PsychologicalMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSchizophreniaYoung AdultConceptsObsessive-compulsive disorderObsessive-compulsive symptomsSchizophrenia patientsPrevalence of OCDSchizophrenia rating scalesPresence of OCSPrevalence of patientsUse of clozapineUse of antidepressantsClinical Global ImpressionPANSS total scoreCross-sectional studyStructured Clinical InterviewHigher severity scoresNegative Syndrome ScaleHigher severityYale-Brown ObsessiveGlobal ImpressionSeverity scorePatientsClozapineClinical InterviewHaloperidolSchizophrenia symptomsSyndrome ScaleAssociation between symptom severity and internal capsule volume in obsessive-compulsive disorder
de Souza Duran F, Hoexter M, Valente A, Miguel E, Busatto G. Association between symptom severity and internal capsule volume in obsessive-compulsive disorder. Neuroscience Letters 2009, 452: 68-71. PMID: 19150484, DOI: 10.1016/j.neulet.2009.01.007.Peer-Reviewed Original ResearchConceptsWhite matter volumeObsessive-compulsive disorderMagnetic resonance imagingMatter volumeCingulum bundleWhite matter volume deficitsPathophysiology of OCDOCD patientsAsymptomatic control subjectsWhite matter reductionThalamic-cortical circuitWhite matter alterationsVoxel-based morphometryWhite matter tractsRegional white matter volumeSymptom severity ratingsInternal capsuleNeurosurgical treatmentSeverity scoreControl subjectsAnterior limbConnectivity dysfunctionT MRI scannerOCD severity scoresVolume deficits